S&C advises Amgen in the largest healthcare merger of 2022

S&C advises Amgen in the largest healthcare merger of 2022

December 16, 2022

In the largest healthcare merger announced this year, S&C is advising biotechnology company Amgen in its pending acquisition of Horizon Therapeutics for an enterprise value of $28.3 billion, with the client prevailing over competing bids. Horizon Therapeutics is a global biotechnology company headquartered in Dublin, Ireland that develops medicines that address critical needs for people affected by rare, autoimmune and severe inflammatory diseases.
 
The cross-border S&C team advising Amgen includes Frank Aquila, Miaoting (Mimi) Wu, Spencer Nord and Andrew Kim. The finance team, which helped secure $28.5 billion in acquisition financing, included Ari Blaut, Presley Warner, Joyce Kwok, Matthew Squire, Hannah Cockle and Dermot Costello. Heather Coleman and Rebecca Rabinowitz are advising on executive compensation. Davis Wang, HyunKyu Kim and Stephen Profeta are advising on tax matters. Nader A. Mousavi, RuiHui (Rachel) Yu, KJ Lim, Jamie Chang, Elizabeth Levin and Elianne Neuman Schiff are advising on intellectual property matters. Renata Hesse, Michael Rosenthal, Alexander Minore, Matt Bogdan and Marielena Doeding are advising on competition matters.
 
S&C has counseled the biotechnology company for nearly two decades, including advising on Amgen’s $1.9 billion acquisition of Five Prime Therapeutics in 2021, its $13.4 billion purchase of the worldwide rights to Otezla in 2019, its $9.7 billion acquisition of Onyx Pharmaceuticals in 2013 and its $2.2 billion purchase of Abgenix in 2005.
 
Our multidisciplinary Healthcare & Life Sciences practice delivers best-in-class services to clients of all sizes, from start-ups to investment funds to the largest global healthcare businesses. We have advised on some of the largest recent deals in this sphere, including Abiomed’s $18 billion pending acquisition by J&J, Biohaven Pharmaceuticals’ $11.6 billion acquisition by Pfizer, Baxter International’s $12.4 billion acquisition of Hillrom, and Haleon's demerger from GSK and landmark European listing creating the world's biggest stand-alone consumer health company.
 
Recent Podcasts and Videos


Subscribe to stay up to date on developments in M&A and Healthcare & Life Sciences.